Insider Transactions in Q2 2022 at Nektar Therapeutics (NKTR)
Insider Transaction List (Q2 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 16
2022
|
John Northcott SVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
4,592
-2.02%
|
$13,776
$3.95 P/Share
|
|
May 16
2022
|
Mark Andrew Wilson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,136
-2.59%
|
$9,408
$3.95 P/Share
|
|
May 16
2022
|
Gil M Labrucherie SVP, COO & CFO |
SELL
Open market or private sale
|
Direct |
17,448
-5.28%
|
$52,344
$3.95 P/Share
|
|
May 16
2022
|
Howard W Robin President & CEO |
SELL
Open market or private sale
|
Direct |
36,529
-5.56%
|
$109,587
$3.95 P/Share
|
|
May 16
2022
|
Jillian B. Thomsen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,841
-3.31%
|
$17,523
$3.95 P/Share
|
|
May 16
2022
|
Jonathan Zalevsky Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
21,673
-7.27%
|
$65,019
$3.95 P/Share
|
|
May 15
2022
|
Gil M Labrucherie SVP, COO & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
28,750
+8.01%
|
-
|
|
May 15
2022
|
Howard W Robin President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
68,450
+9.43%
|
-
|
|
May 15
2022
|
Jillian B. Thomsen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,950
+5.85%
|
-
|
|
May 15
2022
|
Jonathan Zalevsky Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,950
+7.44%
|
-
|